Northern Trust’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Northern Trust’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-31,442	Closed	-$56.9K	–	4567
2023 Q2	$56.9K	Sell	31,442 -214,811	-87%	-$393K	﹤0.01%	4192
2023 Q1	$325K	Sell	246,253 -209	-0.1%	-$342	﹤0.01%	3630
2022 Q4	$417K	Sell	246,462 -12,623	-5%	-$16K	﹤0.01%	3562
2022 Q3	$479K	Buy	259,085 +26,114	+11%	+$77.9K	﹤0.01%	3527
2022 Q2	$715K	Buy	232,971 +182,875	+365%	+$1.12M	﹤0.01%	3433
2022 Q1	$362K	Buy	+50,096	New	+$493K	﹤0.01%	3866

Other funds holding PRDS

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Northern Trust's PRDS Position: Q3 2023 in Review

Northern Trust sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q3 2023, closing a stake of 31,442 shares — an estimated $56.9K sold.

Northern Trust first reported a position in PRDS in Q1 2022 and held it in 6 quarters. The position peaked at $715K in Q2 2022. 1 fund tracked by Wall St. Rank holds PRDS as of Q3 2023.

Northern Trust reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Northern Trust sold 31,442 Pardes Biosciences, Inc. Common Stock shares in Q3 2023, an estimated $56.9K.
Northern Trust first reported a position in Pardes Biosciences, Inc. Common Stock in Q1 2022 and held it in 6 quarters.
Northern Trust's Pardes Biosciences, Inc. Common Stock position peaked at $715K in Q2 2022.
1 fund tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q3 2023.

Based on Northern Trust's 13F filing for Q3 2023, filed 13 Nov 2023.